ABSTRACT
Background Norovirus and sapovirus are important causes of childhood acute gastroenteritis (AGE). Breastfeeding prevents AGE generally; however, it is unknown if breastfeeding prevents AGE caused specifically by norovirus and sapovirus.
Methods We investigated the association between breastfeeding and norovirus or sapovirus AGE episodes in a birth cohort. Weekly data on breastfeeding and AGE episodes were captured during the first year of life. Stools were collected from children with AGE and tested by RT-qPCR for norovirus and sapovirus. Time-dependent Cox models estimated associations between weekly breastfeeding and time to first norovirus or sapovirus AGE.
Findings From June 2017 to July 2018, 444 newborns were enrolled in the study. In the first year of life, 69 and 34 children experienced a norovirus and a sapovirus episode, respectively. Exclusive breastfeeding lasted a median of 2 weeks, and any breastfeeding lasted a median of 42 weeks. Breastfeeding in the last week did not prevent norovirus (HR: 1.09, 95% CI: 0.62, 1.92) or sapovirus (HR: 1.00, 95% CI: 0.82, 1.21) AGE in a given week, adjusting for household sanitation, consumption of high-risk foods, and mother’s and child’s histo-blood group phenotypes. Maternal secretor-positive phenotype was protective against norovirus AGE, whereas child’s secretor-positive phenotype was a risk factor for norovirus AGE.
Interpretation Exclusive breastfeeding in this population was short-lived, and no conclusions could be drawn about its potential to prevent norovirus or sapovirus AGE. Non-exclusive breastfeeding did not prevent norovirus or sapovirus AGE in the first year of life. However, maternal secretor-positive phenotype was associated with a reduced hazard of norovirus AGE.
WHAT IS KNOWN
– Breastfeeding prevents acute gastroenteritis (AGE) in nursing infants.
– It is unknown if breastfeeding prevents AGE caused by norovirus or sapovirus, which are leading causes of childhood AGE worldwide.
– Host genetic factors can influence AGE risk, and the mediating effects of breastfeeding are unclear.
WHAT IS NEW
– Exclusive breastfeeding was rare, and breastfeeding did not prevent norovirus (hazard ratio 1.09, 95% CI: 0.62, 1.92) or sapovirus (hazard ratio 1.00, 95% CI: 0.82, 1.21) AGE.
– Secretor-positive phenotype of the child and the mother may be more important than breastfeeding in determining norovirus and sapovirus AGE risk in this setting.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by award R01AI127845 from the National Institute of Allergy and Infectious Diseases (NIAID). SBD is supported by K24AI141744 from NIAID FG, YR, and LG are supported by an international research capacity-building award from the NIH-Fogarty International Center, D43TW010923. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. https://www.niaid.nih.gov/ https://www.fic.nih.gov/
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Institutional Review Boards at the University of North Carolina School of Medicine (IRB #: 20-0698), the National Autonomous University of Nicaragua (UNAN)-León (IRB #: 00003342) and CDC (Research determination: 0900f3eb81c526a7). Written informed consent was provided by the mother or legal guardian of infants enrolled in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
↵* Co-first author
↵† Co-senior author
Conflicts of Interest: The author have no conflicts of interest to declare.
Funding Sources: This study was supported by award R01AI127845 from the National Institute of Allergy and Infectious Diseases (NIAID). SBD is supported by K24AI141744 from NIAID; FG, YR, and LG are supported by an international research capacity-building award from the NIH-Fogarty International Center, D43TW010923.
Data Availability
Data cannot be shared publicly because it contains identifying information about children enrolled in the birth cohort and their relatives, including full names and dates of birth. Data are available on request from the lead and senior authors with approval by the Ethics Committees of the University of North Carolina at Chapel Hill and the National Autonomous University of Nicaragua in Leon for researchers who meet the criteria for access to confidential and de-identified data.
